AFT Pharmaceuticals reports ongoing sales growth and R&D progress

• On track to reach $300M FY27 revenue target
• Longer term growth supported by full product launch pipeline
• Novel iron injectable product passes regulatory hurdles
• R&D pipeline further strengthened

AFT Pharmaceuticals (ASX:AFP) has reported sustained growth in the first quarter of the 2027 financial year, remaining on track to reach its $300 million FY27 annual revenue target.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

MD, Dr Hartley Atkinson, said the company is backed by a full program of product launches, spanning both internally developed and in-licensed products, laying the foundations to extend record of growth, which has averaged 17% per year over the past two decades.

“We are pleased with our quarterly sales progress and the advances we have made in our R&D pipeline of, now, eight patented products that together offer the potential of significant long-term value to the business,” he said.

“Across our operations in Australia, New Zealand, Singapore, Hong Kong, South Africa, Canada and the United Kingdom we have submitted regulatory filings for 86 new products, and we are preparing to file for a further 138 products.

“We are also awaiting data that will precipitate a further 145 regulatory filings across our markets in the next couple of years. These filings are in addition to those that will follow from our own R&D pipeline.”

Dr Atkinson told shareholders the product launches are concentrated in the company’s new business hubs in international and Asian markets where AFT expects the highest rates of year-on-year growth.

“However, our confidence in our core markets of Australia and New Zealand, which respectively grew by 19% and 11% in the FY26 financial year, remains strong,” he said.

“Our international efforts are supported by continued investments in market development. For example, we have recently appointed a senior marketing manager in the UK to assist with growth in Northern Hemisphere markets.”

Dr Atkinson added that momentum is building around the company’s new injectable iron research and development project, one of the most exciting projects in the company’s R&D portfolio, offering a potential market worth as much as US$7.4 billion.

The US Food and Drug Administration (FDA) has reviewed AFT’s Investigational New Drug (IND) application for the project, allowing the company to proceed with its global Phase III clinical confirmatory trial.

AFP was steady at $3.04 with a Mkt cap $318.7M prior to markets opening.

Join the discussion: See what HotCopper users are saying about AFT Pharmaceuticals and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.